Evotec and Janssen team up in immunoncology
Evotec SE and Janssen Biotech Inc have agreed to co-develop targeted immuno-oncological therapies.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1996 entries already.
Entries by Thomas Gabrielczyk
Evidence of deliberate climate damage
A new study adds weight to ongoing legal and political investigations against ExxonMobil for deliberate climate malfeasance.
Rewind Therapeutics extends Series A financing
With Sunstone Life Siences A/S as a new investor, Belgian remyelination specialist Rewind Therapeutics has increased its 2018 Series A funding.
New polymer can stop biofilm formation
British researchers have created a new polymer material that may help to prevent urinary tract infections caused by catheters
Henkel buys FDCA from Avantium NV
Bioplastics specialist Avantium N.V. has inked a 5-year agreement to supply Henkel with plant sugar based furandicarboxylic acid , a building block of PEF bioplastics.
Ultra-low freezers: Stability of cancer biomarkers
Maintaining the integrity of tumour biomarkers during processing and storage is of great importance for the accurate diagnosis and prognosis of many diseases, including cancers. To safely store samples for research or clinical uses, freezing procedures are used to arrest the degradation of biomarkers. However, the stability of these molecules depends upon long-term storage conditions.
New partnerships push InDevR for Series B financing
InDevR Inc., a provider of analytical technologies for vaccines and biotherapeutics, has raised $9m in Series B financing.
Vésale Bioscience wins R&D grant
Phage therapy specialist Vésale Bioscience gas bageds €1.8m from European Innovation Council (EIC) to fight antibiotic resistance (AMR).
Its on: the race for sustainable packaging
A decade ago, the news about the Great Pacific Garbage Patch went viral. Since then, a multitude of startups proliferated on a mission to create ecological alternatives to the ubiquitous fossil-based plastics. At ECBF, we are closely monitoring the emerging materials for packaging applications, by far the main use case of plastics.
Abionyx Pharma announces success in fighting sepsis-triggered AKI
Abionyx Pharma SA has announced positive data from Phase IIa testing of iCER-001, a recombinant apoA-I, as a treatment for septic patients at high risk of developing Acute Kidney Injury (AKI)